[Combination of ketamine and esketamine with Exposure and Response Prevention (ERP) therapy for Obsessive-Compulsive Disorder].

Combinaison de la kétamine et de l’eskétamine avec la thérapie d’exposition avec prévention de la réponse (EPR) dans le trouble obsessionnel-compulsif.
EPR ERP Exposition avec prévention de la réponse Exposure and response prevention psychotherapy Extinction de la peur Fear extinction Ketamine Kétamine NMDA receptor OCD Obsessional-compulsive Disorder Récepteur NMDA TOC Trouble obsessionnel compulsif

Journal

L'Encephale
ISSN: 0013-7006
Titre abrégé: Encephale
Pays: France
ID NLM: 7505643

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 30 06 2021
revised: 24 07 2022
accepted: 04 08 2022
medline: 22 5 2023
pubmed: 25 4 2023
entrez: 24 04 2023
Statut: ppublish

Résumé

Obsessive-Compulsive Disorder (OCD), characterized by the combination of obsession and compulsion, is a clinical and therapeutic challenge. Many patients with OCD do not respond to first-line treatments such as serotonin selective reuptake inhibitors (SSRIs) and exposure and response prevention psychotherapy (ERP). For these resistant patients, some preliminary studies have shown that ketamine, a non-selective glutamatergic NMDA receptors antagonist, could improve the obsessive symptoms. A number of these studies have also suggested that the combination of ketamine with ERP psychotherapy may jointly potentiate the effectiveness of ketamine and ERP. In this paper, we present the existing data on the combined use of ketamine with ERP psychotherapy for OCD. We suggest that modulation of NMDA receptor activity and glutamatergic signaling by ketamine may promote the therapeutic mechanisms involved in ERP such as fear extinction and brain plasticity mechanisms. Finally, we propose a ketamine-augmented ERP psychotherapy (KAP-ERP) protocol in OCD, and we present the limitations associated with its application in clinical practice.

Identifiants

pubmed: 37095049
pii: S0013-7006(22)00180-4
doi: 10.1016/j.encep.2022.08.011
pii:
doi:

Substances chimiques

Esketamine 50LFG02TXD
Ketamine 690G0D6V8H

Types de publication

English Abstract Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

304-311

Informations de copyright

Copyright © 2022 L'Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Hugo Bottemanne (H)

Paris Brain Institute - Institut du Cerveau (ICM), UMR 7225/UMRS 1127, Sorbonne University/CNRS/Inserm, Paris, France; Sorbonne University, Department of Philosophy, SND Research Unit, UMR 8011, CNRS, Paris, France; Department of Psychiatry, Pitié-Salpêtrière Hospital, Sorbonne University, DMU Neuroscience, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. Electronic address: hugo.bottemanne@sorbonne-universite.fr.

Alice Arnould (A)

Department of Psychiatry, Pitié-Salpêtrière Hospital, Sorbonne University, DMU Neuroscience, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Amaury Najar (A)

Department of Psychiatry, Pitié-Salpêtrière Hospital, Sorbonne University, DMU Neuroscience, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Fanny Delaigue (F)

Department of Psychiatry, Pitié-Salpêtrière Hospital, Sorbonne University, DMU Neuroscience, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Laure Serresse (L)

Sorbonne University, Unité Mobile d'Accompagnement et de Soins Palliatifs, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.

Lucie Joly (L)

Paris Brain Institute - Institut du Cerveau (ICM), UMR 7225/UMRS 1127, Sorbonne University/CNRS/Inserm, Paris, France; Department of Psychiatry, Saint Antoine Hospital, Sorbonne University, DMU Neuroscience, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Stéphane Mouchabac (S)

Paris Brain Institute - Institut du Cerveau (ICM), UMR 7225/UMRS 1127, Sorbonne University/CNRS/Inserm, Paris, France; Department of Psychiatry, Saint Antoine Hospital, Sorbonne University, DMU Neuroscience, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH